Prime Medicine (PRME) Stock Price, News & Analysis

Company Overview

Prime Medicine, Inc. is a biotechnology company developing genetic medicines using its proprietary Prime Editing platform. The company’s technology is designed to make precise changes to DNA, including the insertion, deletion, or replacement of genetic sequences, with the goal of addressing disease-causing mutations.

Prime Medicine is focused on developing treatments for genetic diseases and other serious conditions. Its research programs use Prime Editing in approaches that may modify a patient’s own cells, including ex vivo cell-editing applications in which cells are edited outside the body and then returned to the patient. The company’s development pipeline has included programs for inherited disorders such as chronic granulomatous disease, as well as potential applications in immunology, oncology, and other therapeutic areas.

Founded in 2019, Prime Medicine is headquartered in Cambridge, Massachusetts. The company was established around Prime Editing technology developed by researchers including David R. Liu, a professor at Harvard University and the Broad Institute of MIT and Harvard. Prime Medicine’s activities are primarily centered on research, clinical development, and potential commercialization of gene-editing therapies.

Key Stats

• Today's Range: $2.88 to $3.14
• 50-Day Range: $2.81 to $3.71
• 52-Week Range: $2.67 to $6.94
• Volume: 3.56 million shs
• Average Volume: 2.94 million shs
• Market Capitalization: $560.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.47
• Consensus Rating: Moderate Buy

Prime Medicine Stock Analysis - MarketRank™

Prime Medicine scored higher than 63% of companies evaluated by MarketBeat, and ranked 310th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Prime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 1 strong buy rating, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Prime Medicine has a consensus price target of $7.47, representing about 141.8% upside from its current price of $3.09.

Amount of Analyst Coverage

Prime Medicine has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Prime Medicine are expected to grow in the coming year, from ($0.96) to ($0.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Prime Medicine is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Prime Medicine is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Prime Medicine has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.10% of the float of Prime Medicine has been sold short.

Short Interest Ratio / Days to Cover

Prime Medicine has a short interest ratio ("days to cover") of 12.31, which indicates bearish sentiment.

Change versus previous month

Short interest in Prime Medicine has recently decreased by 12.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prime Medicine does not currently pay a dividend.

Dividend Growth

Prime Medicine does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.36

News Sentiment

Prime Medicine has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Prime Medicine this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for PRME on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prime Medicine insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.04% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PRME
• Previous Symbol: NASDAQ:PRME
• CIK: 1894562
• Web: primemedicine.com
• Phone: (617) 465-0013
• Fax: N/A
• Employees: 146
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Prime Medicine: $7.47
• High Price Target: $11.00
• Low Price Target: $4.25
• Potential Upside/Downside: +141.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$201.14 million
• Net Margins: -4,613.11%
• Pretax Margin: -4,613.11%
• Return on Equity: -188.27%
• Return on Assets: -59.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.05
• Quick Ratio: 3.05

Sales & Book Value

• Annual Sales: $4.63 million
• Price / Sales: 121.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 4.61

Miscellaneous

• Outstanding Shares: 181,380,000
• Free Float: 152,284,000
• Market Cap: $560.46 million
• Optionable: N/A
• Beta: 2.34